The website you are linking to is neither owned nor controlled by Astellas or Pfizer. Neither Astellas nor Pfizer are responsible for the content or services on this site.
This link is provided as a convenience to the users of this site.
The reprint you are linking to contains data from a company-sponsored multinational, randomized, double-blind, additional trial in metastatic CRPC for XTANDI® (enzalutamide)—a product co-promoted by Pfizer Inc. and Astellas Pharma US, Inc.
This reprint includes information that is not contained in the approved product labeling. Please see Full Prescribing Information for XTANDI.